Abstract 724
Background
Screening and management of distress are essential. The Distress thermometer (DT) is a common screening tool. However, it’s cutoff score and the accuracy properties such as sensitivity and specificity is still unclear in Chinese cancer patients.
Methods
In this cross-sectional study, DT was compared against the Hospital Anxiety and Depression Scale (HADS) in 784 heterogeneous cancer inpatients. The HADS cutoff score ≥15, ≥6, and ≥9 were used to define distress, anxiety, and depression respectively. Receiver operating characteristic (ROC) analysis was applied to determine the discriminative accuracy of DT against each scale.
Results
When DT was compared against HADS-T, ROC showed an excellent area under the curve (AUC) of 0.903. The optimal cutoff score of 4 yielded sensitivity (SE)=89.3%, specificity (SP)=85.8%, positive predictive value (PPV)=89.9%, negative predictive value (NPV)=85.0%, screening utility (UI-)=.729, and case-finding utility (UI+)=.802. Furthermore, compared With HADS subscales, AUC=0.801 with a cutoff score 3 on DT optimally detected SE = 80.7%, SP = 64.5% PPV=89.4%, NPV=47.3%, UI-=.369, andUI + =.721 for anxiety and AUC=0.802 with a cutoff score of 4 on DT optimally detected SE = 88.3%, SP = 65.3%, PPV=66.4%, NPV=87.8%, UI-=.573 and UI + =.586 for depression respectively. DT Scores were moderately correlated with HADS-Total, HADS-Anxiety, andHADS-Depression. Female gender, low education level, advanced cancer stage, no exercise habit, suicidal ideation and months since diagnosis more than 12 were found to be associated with distress.
Conclusions
For Chinese patients with cancer, DT is an efficacious screening and case finding a tool for distress. Among the subscales, DT performed well in both screening and case finding for depression, however, although the case finding was good it carried a poor screening ability for anxiety.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract